Patents by Inventor Olga De La Rosa

Olga De La Rosa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mesenchymal stem cell-derived exosomes and their uses
    Patent number: 11857575
    Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 2, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans, Javier Garcia Casado, Rebeca Blazquez Duran, Francisco Miguel Sanchez Margallo
  • Lymphocyte biomarkers for determining the clinical response to cell therapy
    Patent number: 11478511
    Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: October 25, 2022
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans
  • IMPROVED STEM CELL POPULATIONS FOR ALLOGENEIC THERAPY
    Publication number: 20220202868
    Abstract: The present invention relates to an improved stem cell population for allogeneic stem cell therapy, in particular for the treatment of presensitized patients and for retreatment. Further, methods for obtaining said stem cell populations are provided. In addition, the present invention relates to pharmaceutical compositions comprising said stem cell populations and their use in allogeneic stem cell therapy.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 30, 2022
    Applicant: TiGenix S.A.U.
    Inventors: Olga DE LA ROSA MORALES, Alvaro AVIVAR-VALDERAS
  • LYMPHOCYTE BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY
    Publication number: 20200261511
    Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.
    Type: Application
    Filed: April 21, 2020
    Publication date: August 20, 2020
    Inventors: Olga DE LA ROSA, Eleuterio LOMBARDO, Wilfried DALEMANS
  • Biomarkers for determining the clinical response to cell therapy
    Patent number: 10746729
    Abstract: The invention relates to a method for predicting the clinical response to a therapy based on the administration of mesenchymal stem cells (MSCs) in a patient suffering from an immune-mediated inflammatory disease. The invention also relates to methods of personalised medicine as well as to therapeutic uses of MSCs in a patient suffering from an immune-mediated inflammatory disease.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: August 18, 2020
    Assignee: TIGENIX, S.A.U.
    Inventors: Olga De La Rosa, Wilfried Dalemans
  • Lymphocyte biomarkers for determining the clinical response to cell therapy
    Patent number: 10660920
    Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 26, 2020
    Assignees: TIGENIX NV, TIGENIX S.A.U.
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans
  • MESENCHYMAL STEM CELL-DERIVED EXOSOMES AND THEIR USES
    Publication number: 20180318354
    Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 8, 2018
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans, Javier Garcia Casado, Rebeca Blazquez Duran, Francisco Miguel Sanchez Margallo
  • BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY
    Publication number: 20180156785
    Abstract: The invention relates to a method for predicting the clinical response to a therapy based on the administration of mesenchymal stem cells (MSCs) in a patient suffering from an immune-mediated inflammatory disease. The invention also relates to methods of personalised medicine as well as to therapeutic uses of MSCs in a patient suffering from an immune-mediated inflammatory disease.
    Type: Application
    Filed: April 25, 2016
    Publication date: June 7, 2018
    Inventors: Olga DE LA ROSA, Wiltried DALEMANS
  • Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
    Patent number: 9969976
    Abstract: A method for the preparation and/or generation of immunomodulatory cells which comprises contacting a mesenchymal stem cell (MSC) and/or fibroblast cell population with peripheral blood leukocytes for between about 2 hours and about 25 days is described herein.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: May 15, 2018
    Assignee: CELLERIX, S.A.
    Inventors: Dirk Buescher, Olga De La Rosa
  • MESENCHYMAL STEM CELL-DERIVED EXOSOMES AND THEIR USES
    Publication number: 20170119682
    Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 4, 2017
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans, Javier Garcia Casado, Rebeca Blazquez Duran, Francisco Miguel Sanchez Margallo
  • MESENCHYMAL STEM CELL-DERIVED EXOSOMES AND THEIR USES
    Publication number: 20170121685
    Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
    Type: Application
    Filed: November 2, 2015
    Publication date: May 4, 2017
    Inventors: Olga DE LA ROSA, Eleuterio LOMBARDO, Wilfried DALEMANS, Javier GARCÍA CASADO, Rebeca BLÁZQUEZ DURÁN, Francisco Miguel SÁNCHEZ MARGALLO,
  • LYMPHOCYTE BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY
    Publication number: 20160067285
    Abstract: The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.
    Type: Application
    Filed: March 17, 2014
    Publication date: March 10, 2016
    Inventors: Olga DE LA ROSA, Eleuterio LOMBARDO, Wilfried DALEMANS
  • Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
    Patent number: 9012220
    Abstract: The present invention relates to cells capable of expressing IDO, nucleic acid constructs for expression of IDO, cells comprising said constructs and methods of utilizing said cells in the treatment of diseases. In particular the present invention relates to cells which express IDO in the absence of exposure to IFN-gamma, and to their use in preparation and/or generation of immunomodulatory cells specific for an antigen.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: April 21, 2015
    Assignee: Cellerix S.A.
    Inventors: Dirk Buescher, Olga De La Rosa, Eleuterio Lombardo
  • CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHODS FOR THE PREPARATION AND USES THEREOF
    Publication number: 20140348808
    Abstract: The present invention relates to immunomodulatory cells, methods for providing immunomodulatory cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof.
    Type: Application
    Filed: May 18, 2012
    Publication date: November 27, 2014
    Inventor: Olga De La Rosa
  • CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES
    Publication number: 20140154227
    Abstract: The present invention provides a population of mesenchymal cells that do not express the cell surface markers CD112 and/or CD155 for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.
    Type: Application
    Filed: March 12, 2012
    Publication date: June 5, 2014
    Inventors: Javier Garcia Casado, Raquel Tarazona Lafarge, Olga De La Rosa
  • CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHODS FOR THE PREPARATION AND USES THEREOF
    Publication number: 20130052174
    Abstract: There is provided inter alia a method for the preparation and/or generation of immunomodulatory cells which comprises contacting a mesenchymal stem cell (MSC) and/or fibroblast cell population with peripheral blood leukocytes for between about 2 hours and about 25 days.
    Type: Application
    Filed: October 22, 2010
    Publication date: February 28, 2013
    Inventors: Dirk Buescher, Olga De La Rosa
  • CELLS, NUCLEIC ACID CONSTRUCTS, CELLS COMPRISING SAID CONSTRUCTS AND METHODS UTILIZING SAID CELLS IN THE TREATMENT OF DISEASES
    Publication number: 20120064031
    Abstract: The present invention relates to cells capable of expressing IDO, nucleic acid constructs for expression of IDO, cells comprising said constructs and methods of utilizing said cells in the treatment of diseases. In particular the present invention relates to cells which expresses IDO in the absence of exposure to IFN-gamma, and to their use in preparation and/or generation of immunomodulatory cells specific for an antigen.
    Type: Application
    Filed: November 6, 2009
    Publication date: March 15, 2012
    Inventors: Dirk Buescher, Olga De La Rosa, Eleuterio Lombardo